Enanta Pharmaceuticals (ENTA) Operating Income (2012 - 2026)
Enanta Pharmaceuticals (ENTA) posted Operating Income of -$11.9 million for Q1 2026, down 5.32% on a QoQ basis from -$11.3 million in Q4 2025, and up 51.68% year-over-year from -$7.8 million in Q1 2025.
Enanta Pharmaceuticals (ENTA) Operating Income (2012 - 2026) Analysis & Trends
Enanta Pharmaceuticals' Operating Income history runs 15 years deep, the most recent figure standing at -$11.9 million for Q1 2026.
- Quarterly Operating Income rose 51.68% year-over-year to -$11.9 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$60.4 million (up 40.86% YoY) and the FY2025 annual result came in at -$85.3 million, up 29.86% from the prior year.
- Operating Income was -$11.9 million for Q1 2026 at Enanta Pharmaceuticals, down from -$11.3 million in the prior quarter.
- Across five years, Operating Income topped out at -$11.3 million in Q4 2025 and bottomed at -$39.5 million in Q1 2023.
- A 5-year average of -$27.1 million and a median of -$29.9 million in 2024 frame the typical range for Operating Income.
- Annual changes were most pronounced in 2023 — Operating Income slipped 16.56% — and 2025, when it surged 52.2%.
- Enanta Pharmaceuticals' Operating Income stood at -$30.0 million in 2022, then slipped by 16.24% to -$34.9 million in 2023, then surged by 32.51% to -$23.5 million in 2024, then jumped by 52.2% to -$11.3 million in 2025, then slipped by 5.32% to -$11.9 million in 2026.
- Business Quant data shows ENTA's Operating Income at -$11.9 million in Q1 2026, -$11.3 million in Q4 2025, and -$18.4 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Op. Inc (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 67,072.09 Bn | 67,072.09 Bn | - | -27.75 Mn |
| 2 | Nanobiotix | 1,894.61 Bn | 1,894.55 Bn | - | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | -15.76 Mn |
| 4 | BeOne Medicines | 471.64 Bn | 466.85 Bn | 1.35 Bn | 249.90 Mn |
| 5 | Vertex Pharmaceuticals | 121.72 Bn | 114.47 Bn | 2.59 Bn | 1.14 Bn |
| 6 | Regeneron Pharmaceuticals | 68.28 Bn | 59.52 Bn | 3.31 Bn | 642.90 Mn |
| 7 | Belite Bio | 61.40 Bn | 61.40 Bn | - | -32.68 Mn |
| 8 | Argenx Se | 56.94 Bn | 56.94 Bn | 1.18 Bn | 394.00 Mn |
| 9 | Revolution Medicines | 37.37 Bn | 37.37 Bn | - | -445.22 Mn |
| 10 | Enanta Pharmaceuticals | 369.97 Mn | 206.20 Mn | - | -11.85 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -11.85 Mn |
| Dec 31, 2025 | -11.25 Mn |
| Sep 30, 2025 | -18.39 Mn |
| Jun 30, 2025 | -18.89 Mn |
| Mar 31, 2025 | -24.53 Mn |
| Dec 31, 2024 | -23.54 Mn |
| Sep 30, 2024 | -29.85 Mn |
| Jun 30, 2024 | -24.19 Mn |
| Mar 31, 2024 | -32.77 Mn |
| Dec 31, 2023 | -34.89 Mn |
| Sep 30, 2023 | -31.03 Mn |
| Jun 30, 2023 | -36.71 Mn |
| Mar 31, 2023 | -39.45 Mn |
| Dec 31, 2022 | -30.01 Mn |
| Sep 30, 2022 | -27.05 Mn |
| Jun 30, 2022 | -32.54 Mn |
| Mar 31, 2022 | -33.85 Mn |
| Dec 31, 2021 | -30.41 Mn |
| Sep 30, 2021 | -33.73 Mn |
| Jun 30, 2021 | -33.85 Mn |